Lihua E. Budde

Also affiliated with City of Hope

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial”.

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

Nature Medicine(2024)10.1038/s41591-024-02979-8

N/A

1.8DataRank · unranked

124 citations

M. Suzette Blanchard, Lauren Adkins, Laura Luebbert, Neena A. Leggett, Stephanie N. Shishido +23 more

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood(2023)10.1182/blood.2023020485

N/A

1.3DataRank · unranked

40 citations

Lu Chen, James Godfrey, Joo Y. Song, Colt A. Egelston, Sandrine Puverel +18 more

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

The Lancet Haematology(2024)10.1016/s2352-3026(24)00171-6

N/A

0.673DataRank · unranked

20 citations

Jasmine Zain, Kerry J. Savage, Tatyana Feldman, Jonathan E. Brammer, Lu Chen +14 more

Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies

Blood Advances(2024)10.1182/bloodadvances.2024013195

N/A

0.176DataRank · unranked

2 citations

Lihua E. Budde, Elizabeth Oh, Szymon J. Szymura, Aaron Anderson, Marissa Morales Del Real +5 more

A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps2665

N/A

0DataRank · unranked

4 citations

Stephen J. Forman, Joycelynne Palmer, Timothy W. Synold, Lei Tian, Ting Lu +14 more

Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

(2023)10.1158/2326-6066.c.6550309

N/A

0DataRank · unranked

0 citations

Christian Huynh, Ryan Urak, Lihong Weng, Miriam Walter, Laura Lim +21 more

Data from The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

(2023)10.1158/2326-6066.c.6550309.v1

N/A

0DataRank · unranked

0 citations

Christian Huynh, Ryan Urak, Lihong Weng, Miriam Walter, Laura Lim +21 more

Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma

American Journal of Hematology(2024)10.1002/ajh.27548

N/A

0DataRank · unranked

13 citations

Reid W. Merryman, Yan Wang, Charles Gaulin, Evandro D. Bezerra, Timothy Voorhees +16 more

Trends in First-Line Use of Radiation Therapy for Early-Stage Gastric Marginal Zone Lymphoma

International Journal of Radiation Oncology*Biology*Physics(2024)10.1016/j.ijrobp.2024.07.1471

N/A

0DataRank · unranked

0 citations

Amanda Schwer, Savita Dandapani, J.Y.C. Wong, Nayel Khan, Avyakta Kallam +11 more

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

Blood Advances(2025)10.1182/bloodadvances.2025017011

N/A

0DataRank · unranked

7 citations

Richard Aplenc, Susanne H.C. Baumeister, Marco Becilli, Anand Bhagwat, Challice L. Bonifant +30 more

The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma

Cancer Immunology Research(2020)10.1158/2326-6066.cir-20-0236

N/A

0DataRank · unranked

46 citations

Christian Huynh, Ryan Urak, Lihong Weng, Miriam Walter, Laura Lim +21 more

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis

Blood Advances(2025)10.1182/bloodadvances.2025016845

N/A

0DataRank · unranked

2 citations

Tamer Othman, Paul Frankel, Christopher Ruel, Christina Poh, Samantha Herbert +20 more

Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2038

N/A

0DataRank · unranked

57 citations

Samer K. Khaled, Xiuli Wang, Joycelynne Palmer, Yan Wang, Jamie R. Wagner +17 more

Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma

American Journal of Hematology(2023)10.1002/ajh.27069

N/A

0DataRank · unranked

34 citations

Stacy Pak, Matthew Mei, Yan Wang, Leslie Popplewell, John H. Baird +13 more

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2022.7100

N/A

0DataRank · unranked

12 citations

Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh +17 more